[Replacement therapy for hepatic failure syndrome].
The results of treatment were studied in 33 patients with hepatic failure syndrome. The patients received MARS therapy or hemodiafiltration as part of intensive care. Albumin dialysis (MARS) may replace hepatic detoxifying function and it is highly effective in diminishing cytolysis in patients with hepatic failure syndrome. Hepatic encephalopathy rapidly regressed with MARS therapy, except for patients with irreversible cerebral changes. The major effect of albumin dialysis is a prompt reducing cytolosis of hepatocytes and liver function stabilization. The most likely mechanisms of action of MARS are the elimination of hydrophobic toxins and the deligandization of albumin molecules, suggesting that MARS is effective in correcting osmotic and colloid ostomic pressures, acid-base balance, microcirculation, and hemodynamics, resulting in a decrease in the concentration of proinflammatory cytokines.
Iampol'skiĭ
A F
AF
Eremeeva
L F
LF
D003422:Critical Care / Q000379:methods*; D005260:Female; D017583:Hemodiafiltration; D006501:Hepatic Encephalopathy / Q000628:therapy*; D006801:Humans; D017093:Liver Failure / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis / Q000379:methods*; D012709:Serum Albumin / Q000032:analysis; D013577:Syndrome; D016896:Treatment Outcome
D012709:Serum Albumin